HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. Ad Regulator Tackles Issue Of Misleading “Touch-Ups” In Beauty Ads

This article was originally published in The Rose Sheet

Executive Summary

An advertising watchdog group in the U.K. is putting forth guidelines intended to quash the use of digital touch-ups and other techniques that exaggerate the effects of cosmetic products and mislead consumers.

You may also be interested in...



Bill Directs FTC To Take Action On Photoshopped Ads

A new bill presented in the House instructs the FTC to examine the use of ads that alter the physical characteristics of the face and body and develop a strategy to address the issue and reduce their use.

ASA Chides Nivea For Retouching Mature Skin In Vital Ad

Nivea owner Beiersdorf defends post-production touch-ups to an older model in advertising for its Nivea Vital anti-aging cream, as the ad did not include quantifiable performance claims or a before-and-after visual comparison. The U.K.’s Advertising Standards Authority maintains the ad should not run again as formatted.

Ad For Diorshow Is A No-Go; ASA Not Warming To Photoshopping

U.K.’s Advertising Standards Authority advises LVMH Moët Hennessy-Louis Vuitton’s Parfums Christian Dior division to discontinue running an ad for Diorshow mascara that features actress Natalie Portman’s digitally enhanced eyelashes. ASA has warned industry in guidance about taking such liberties post-production that could inflate consumer expectations for product performance.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel